Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18082551 | 0.86 | LTA4H (0.55) | LTA4HLMNAPOLBALDH1A1MEN1 | |
| SCHEMBL13285981 | 0.84 | SIGMAR1 (0.62) | LTA4HLMNAPOLBALDH1A1DRD4 | |
| SCHEMBL28369901 | 0.84 | LTA4H (0.50) | S1PR1S1PR5LTA4HGBA1SIGMAR1 | |
| SCHEMBL18491559 | 0.84 | LTA4H (0.50) | LTA4HPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL27786435 | 0.83 | LTA4H (0.56) | S1PR1S1PR5LTA4HLMNAPOLB | |
| SCHEMBL12082512 | 0.82 | ALDH1A1 (0.56) | LTA4HLMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2919409 | 0.81 | S1PR1 (0.48) | S1PR1S1PR5LTA4HLMNAPOLB | |
| SCHEMBL12449596 | 0.81 | LTA4H (0.48) | S1PR1S1PR5LTA4HALDH1A1SIGMAR1 | |
| SCHEMBL21092816 | 0.81 | LTA4H (0.48) | S1PR1S1PR5LTA4HALDH1A1MEN1 | |
| SCHEMBL1936810 | 0.81 | NCF1 (0.57) | LTA4HMEN1KMT2AHRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
| EP-2499146-B1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO SA (CH) | 2016-09-21 | — | — | EP | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | S1PR1 577/4885S1PR5 883/4885LTA4H 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.